| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
Topline Data Readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Topline Data Readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Nervous System | ||
Topline Data Readout example | Phase 1b | — | Subscribe to access the data. | Small Molecules | Nervous System |
Recent Updates
Recently added Catalysts
Gain Therapeutics, Inc.$1.8
0 (0%)
D 24Pipeline Score Overvalued Biotech · Commercial
Market Cap
75.92 M
EPS
-0.59
P/E Ratio
-
Value Trade
674.63 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.76 M
Operating CF
-4.73 M
Total Assets
18.74 M
Total Liabilities
4.73 M
Equity
14.01 M
D/E Ratio
12,345
-2.2 %
Week
-16.04 %
1 Month
-6.81 %
3 Month
-37.1 %
6 Month
-83.25 %
5 Year
-84.14 %
All Time
Cash Data
Cash Position
16.54 M
Monthly Burn
1.58 M
Runway
8.7 mo
Burn Trend
StableSEC Filing
May 11, 2026
Overview
Volume
610.32 K
52 Week Range
1.41 - 4.34
% held by Insiders
3 %
% held by Institutions
19.56 %
Enterprise Value
60.06 M
Total Shares
42.67 M
Short %
8.83 %
Float Shares
40.88 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Gain Therapeutics, Inc.
192Total events
5Upcoming
18Tier-1 (high impact)
2021 – 2026Coverage
Upcoming catalysts 5
Sep 2026
T2Trial Completion
Phase 1b nine-month extension study expected to complete in September 2026
Event history 187
Q3 2026
◆Trial InitiationLow Dose GT-02287Trial
Initiation of Phase 2a study of GT-02287 expected in 3Q26
Parkinson's diseasesource ↗
Jun 29, 2026
▲IND ClearanceLow Dose GT-02287IND
FDA clearance of IND for GT-02287 Phase 2 in Parkinson's disease
Parkinson's diseasesource ↗
Jun 15, 2026
◆Oral PresentationPresentation
Gain Therapeutics to present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
May 24, 2026
◆Oral PresentationPresentation
Management attendance at 7th World Parkinson’s Congress
Parkinson's diseasesource ↗
May 22, 2026
◆Oral PresentationLow Dose GT-02287Presentation
Oral presentation at 3rd International GBA1 Meeting 2026
Parkinson's diseasesource ↗
May 22, 2026
◆Topline ReadoutLow Dose GT-02287Clinical Data
Interim data from Phase 1b study extension (Day 150) presented
Parkinson's diseasesource ↗
May 2026
◆Oral PresentationLow Dose GT-02287Presentation
Presentation at 3rd International GBA1 Meeting later this month
Parkinson's diseasesource ↗
Apr 24, 2026
▲Trial InitiationLow Dose GT-02287Trial
Phase 1b extension study commenced
Parkinson's diseasesource ↗
Apr 24, 2026
▲Topline ReadoutLow Dose GT-02287Clinical Data
Initial results from Phase 1b clinical trial
Parkinson's diseasesource ↗
Apr 2026
◆FDA Feedback ReceivedLow Dose GT-02287FDA Meeting
FDA response expected within weeks after March 2026 IND submission
Parkinson's diseasesource ↗
Q2 2026
◆IND ClearanceLow Dose GT-02287IND
FDA clearance of IND expected in Q2 2026
Parkinson's diseasesource ↗
Drug Pipeline Intelligence
D24
Pipeline Score $4M
Pipeline ValueOvervalued
Valuation Signal1
Drugs Scored0.2x
rNPV / MCap Top 23%
Micro Cap (rank 702 of 911)
Percentile RankGain Therapeutics, Inc. faces pipeline headwinds (24/100), with $92M risk-adjusted pipeline value, led by Low Dose GT-02287 in Parkinson Disease (Phase 2).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Low Dose GT-02287 Small molecule | Parkinson Disease | Phase 2 | NCT07280299 | 11% | $92M | NOT YET_RECRUITING | 131 | VERY_FAST | B (65) | Jun 30, 2028 | LOW_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
GT-02287 | Parkinson's disease | Phase 1b | 2026-06-29 | 81% reduction in cerebrospinal fluid (CSF) glucosylsphingosine (GluSph) after 90 days; All 16 participants who entered the ongoing Phase 1b extension study remained on study at Day 150 Read More | Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease Read More | |
GT-02287 | Parkinson's disease | Phase 1b | 2026-06-29 | 81% reduction in cerebrospinal fluid (CSF) glucosylsphingosine (GluSph) after 90 days; All 16 participants who entered the ongoing Phase 1b extension study remained on study at Day 150 Read More | Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease Read More | |
GT-02287 | Parkinson's disease | Phase 1b | 2026-06-29 | 81% reduction in cerebrospinal fluid (CSF) glucosylsphingosine (GluSph) after 90 days; All 16 participants who entered the ongoing Phase 1b extension study remained on study at Day 150 Read More | Gain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in GANX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
GANX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
GANXGain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
Gain Therapeutics has received FDA clearance for its IND application to advance GT-02287 into Phase 2 clinical development for Parkinson's disease. This decision follows positive Phase 1 results indicating both safety and efficacy. The Phase 2 study is expected to begin in the third quarter of 2026, involving participants from the U.S., Australia, and Europe.
Read more →GANXParkinson’s Disease vs. Shrinking: What the Show Gets Right (and Wrong) About a Complex Condition
The article analyzes the portrayal of Parkinson's disease in the series 'Shrinking,' highlighting its blend of humor and emotional depth. While the show effectively captures the unpredictability and psychological aspects of living with the disease, it simplifies certain realities, such as the timeline of progression and the full range of symptoms. Overall, it emphasizes the humanity behind the diagnosis.
Read more →GANXGain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Gain Therapeutics, Inc. will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit on June 15-16, 2026. CEO Gene Mack will engage in a virtual fireside chat and one-on-one meetings. The company is focused on developing allosteric therapies, with its lead candidate GT-02287 currently in a Phase 1b trial for Parkinson's disease.
Read more →GANXGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
Gain Therapeutics has presented encouraging interim data from its Phase 1b clinical study of GT-02287 at the 3rd International GBA1 Meeting. The study demonstrated that MDS-UPDRS scores remained stable after 150 days of treatment, with notable benefits reported by participants in areas such as smell, taste, and balance. Comparisons revealed significant differences in scores between those with low and high baseline glucosylsphingosine levels. The continuing development of GT-02287 aims to address the underlying biology of Parkinson's disease.
Read more →GANXGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
Gain Therapeutics reported its financial results for Q1 2026, highlighting advancements in its lead candidate GT-02287 for Parkinson's disease. The ongoing Phase 1b study shows promising biomarker data and stable MDS-UPDRS scores. The company anticipates FDA clearance for its IND in Q2 2026, with a Phase 2 study expected to commence in Q3 2026.
Read more →GANXWhat to Do After Being Diagnosed With Parkinson’s: Treatment, Lifestyle and Support
The article discusses the increasing prevalence of Parkinson's disease and offers a comprehensive guide for newly diagnosed individuals. It outlines essential steps to take post-diagnosis, including understanding the condition, scheduling follow-up appointments with specialists, exploring treatment options, and making lifestyle changes. The importance of emotional support and creating a personalized care plan is emphasized, along with the need to stay hopeful amidst ongoing research.
Read more →GANXParkinson’s Disease KOL Event
Gain Therapeutics hosted a KOL event discussing their Parkinson's disease treatment GT-02287. The ongoing Phase 1b study in Australia is assessing its safety and tolerability among patients. Preliminary data shows promising engagement of GCase activity, which may indicate potential for disease modification. The study has enrolled 21 participants, with most experiencing mild adverse events.
Read more →GANXGain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
Gain Therapeutics announced an oral presentation at the 3rd International GBA1 Meeting 2026, highlighting their lead drug candidate, GT-02287, for Parkinson's disease. The drug has shown promising results in preclinical models and is currently in a Phase 1b clinical trial. Initial findings indicate favorable safety, tolerability, and potential disease-modifying effects.
Read more →GANXGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2025 and Provides Corporate Update
Gain Therapeutics reported its financial results for Q4 and the year ending December 31, 2025, highlighting progress in the development of GT-02287 for Parkinson's disease. The company noted stable MDS-UPDRS scores and significant reductions in glucosylsphingosine levels in patients. Looking ahead, they anticipate starting Phase 2 trials in Q3 2026 and have ongoing engagements with the FDA.
Read more →GANXGain Therapeutics to Present at the 38th Annual ROTH Conference
Gain Therapeutics, Inc. announced that its President and CEO, Gene Mack, will participate in a fireside chat and one-on-one meetings at the 38th Annual ROTH Conference from March 22-24, 2026. The company is focused on developing allosteric therapies, with its lead candidate GT-02287 currently in a Phase 1b trial for Parkinson's disease. Gain's unique drug discovery platform aims to address various neurodegenerative and genetic disorders.
Read more →GANX▼ -25.6%on this newsshared move
Gain Therapeutics Presents Additional Clinical and Biomarker Data from Phase 1b Clinical Study of GT-02287 and Preclinical Data from Novel Chemical Series at AD/PD 2026 Additional biomarker analysis reveals higher CSF le
Gain Therapeutics presented additional clinical and biomarker data on GT-02287 at the AD/PD 2026 conference. The Phase 1b study indicated a reduction in glucosylsphingosine levels and stable MDS-UPDRS scores after continued treatment. Additionally, preclinical data from a new chemical series, led by GT-04686, was revealed as it prepares for IND-enabling studies for Parkinson's disease. Both the ongoing trial and the novel compounds suggest promising avenues for disease modification in managing Parkinson's disease.
Read more →GANXGain Therapeutics Announces Presentations at AD/PDTM 2026 and Provides U.S. FDA Regulatory Update
Gain Therapeutics announced its participation in the AD/PD 2026 conference, where it will present findings from its Phase 1b study of GT-02287 for Parkinson's disease. The company is also preparing to initiate a Phase 2 clinical trial after submitting additional data to the FDA. The drug candidate aims to modify disease progression rather than just alleviate symptoms.
Read more →GANXGain Therapeutics to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Gain Therapeutics, Inc. will participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference, which takes place on February 25-26, 2026. The company management will engage in a fireside chat and individual meetings with attendees to discuss their advancements in allosteric small molecule therapies. Notably, Gain's lead candidate, GT-02287, is being evaluated for Parkinson's disease in a Phase 1b clinical trial, with potential applications in other neurodegenerative conditions. For those unable to attend, Gain has provided alternative meeting arrangements for investor communication.
Read more →GANXCorporate Presentation September 2024 GAIN THERAPEUTICS Corporate Deck February 2026 NASDAQ: GANX © © 2 0 2 6 2 0 2 5 - -G AG A I N T H E R A P E U T I C S I N T H E R A P E U T I C S 22 Certain statements set
GAIN Therapeutics has released a corporate presentation detailing the progress of their investigational drug GT-02287 for Parkinson's disease. The ongoing Phase 1b trial has shown promising results, with patients experiencing significant reductions in glucosylceramide levels and improvements in clinical measures such as the MDS-UPDRS scores. The study evaluates the safety and efficacy of the drug, with plans for a Phase 2 trial set to initiate in the second half of 2026, further investigating the drug's tolerability and biological effects. The company is well-supported by various research foundations and maintains a solid financial position.
Read more →GANX▼ -5.5%on this news· ran to -16% by day 3
Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week
Gain Therapeutics, Inc. announced its participation in several conferences during the J.P. Morgan Healthcare Conference week, including the Sachs Neuroscience Innovation Forum and the Biotech Showcase. The company is advancing its lead drug candidate, GT-02287, which is in a Phase 1b clinical trial for Parkinson's disease. GT-02287 has shown potential in preclinical models and has received funding support from various foundations.
Read more →GANX▼ -14.1%on this newsshared move
Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287
Gain Therapeutics reported new biomarker data supporting the disease-modifying potential of its treatment GT-02287 for Parkinson's disease. In a Phase 1b trial, participants showed an 81% decrease in glucosylsphingosine levels and improvements in movement disorder scores. While the study was not designed to assess clinical efficacy, the results mark a promising step for continued clinical development. The company plans an extension of the study for longer-term outcomes.
Read more →GANX▼ -6.6%on this news· ran to -23% by day 3shared move
Neuroscience 2025: Key Themes, Emerging Trends, and Gain Therapeutics’ Latest Findings
Neuroscience 2025, held in San Diego, gathered thousands of professionals to discuss key themes in neuroscience, including neurodevelopment, aging, and neurotechnology. The conference highlighted significant advancements and emerging trends, particularly in AI-driven research and neurodegenerative disease models. Gain Therapeutics presented new findings on a small-molecule modulator related to Parkinson's disease.
Read more →GANX▼ -44.4%on this news
Gain Therapeutics Announces Positive Results in Key Exploratory Endpoint from its Phase 1b Clinical Study of GT-02287 in People with Parkinson’s Disease
Gain Therapeutics announced positive results from its ongoing Phase 1b clinical study of GT-02287 in Parkinson's disease, showing a significant reduction in glucosylsphingosine levels in cerebrospinal fluid. This marks the first observation of such an effect following the administration of a GCase modulator to patients with Parkinson's disease. The study indicates improved GCase activity in the brain, with potential implications for slowing disease progression. Gain Therapeutics plans to present more detailed findings at upcoming industry events.
Read more →GANX▼ -44.4%on this news
Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson’s Disease
Gain Therapeutics announced a virtual KOL event to discuss their lead drug candidate, GT-02287, aimed at treating Parkinson's disease. The event will feature prominent experts who will review biomarker results from a Phase 1b clinical study that suggests disease-modifying potential for the drug. Insights from the trial reveal that GT-02287 improves GCase enzyme function and demonstrates favorable safety in earlier studies. This event is scheduled for January 6, 2026, and aims to provide a comprehensive overview of the current findings and the future of GT-02287 in treating Parkinson's disease.
Read more →GANXGain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2025
Gain Therapeutics presented new preclinical data on GT-02287 at Neuroscience 2025, highlighting its ability to reduce mitochondrial stress and enhance neuronal survival in Parkinson's disease models. The findings suggest that GT-02287 facilitates the trafficking of glucocerebrosidase to mitochondria, potentially offering a disease-modifying effect. The company is optimistic about the drug's future clinical evaluations.
Read more →GANX▲ +10.1%on this news
Gain Therapeutics Reports Financial Results for Third Quarter 2025 and Provides Corporate Update
Gain Therapeutics reported positive progress in its Phase 1b study of GT-02287 for Parkinson's disease, showing promising initial data suggesting a disease-slowing effect. The company completed enrollment of 21 participants and received approval to extend the study duration to 12 months. Financial results indicate increased R&D expenses, but participant engagement remains strong.
Read more →GANX3 Easy Ways to Adapt Your Home for People with Parkinson’s
The article discusses practical ways to adapt homes for individuals with Parkinson's disease, emphasizing safety, mobility, and emotional well-being. It outlines three main areas for modification: enhancing safety in everyday spaces, improving mobility and accessibility, and ensuring emotional comfort. These adaptations aim to create a supportive living environment that promotes independence and reduces risks associated with the disease.
Read more →GANXGain Therapeutics to Present at Neuroscience 2025
Gain Therapeutics, Inc. will present a poster on GT-02287 at Neuroscience 2025, highlighting its potential as a treatment for Parkinson's disease. The drug has shown promise in preclinical studies and is currently in a Phase 1b trial. The presentation will take place on November 19, 2025, in San Diego, CA.
Read more →GANXAdvancing Global Dialogue in Neurology: A Preview of the MDS Congress 2025
The MDS Congress 2025 will be held in Honolulu from October 5-9, focusing on advancements in movement disorders. It will feature a diverse scientific program, including sessions on disease pathophysiology, biomarkers, and innovative therapies. The congress aims to foster global collaboration among clinicians, researchers, and industry professionals to enhance understanding and treatment of these conditions.
Read more →GANXGain Therapeutics to Attend the 2025 Maxim Growth Summit
Gain Therapeutics, Inc. will attend the 2025 Maxim Growth Summit on October 22-23. CEO Gene Mack will participate in a panel discussing innovative therapies for neurodegenerative diseases. The summit will feature industry leaders and discussions on various sectors, including biotechnology. Gain is focused on developing allosteric therapies, with its lead candidate currently in a Phase 1b trial for Parkinson's disease.
Read more →GANX▲ +7.4%on this newsshared move
Corporate Presentation September 2024 GAIN THERAPEUTICS Parkinson's Disease KOL Event Biomarkers, Clinical Endpoints, and the Path to Disease Modification Contextualizing the emerging data from GT - 02287
Gain Therapeutics presented an overview of their development strategy for GT-02287, focusing on its implications for Parkinson's disease. The presentation featured discussions on emerging data, the significance of biomarkers in early detection, and clinical outcomes using the MDS-UPDRS scale. Key opinion leaders participated to contextualize the data and outline the path towards disease modification. The presentation also cautioned about the uncertainties associated with the forward-looking statements concerning product development and market potential.
Read more →GANX▲ +15.6%on this newsshared move
Gain Therapeutics Presents Initial Data from Phase 1b Clinical Study of GT-02287 in Parkinson’s Patients at International Congress of Parkinson’s Disease and Movement Disorders®
Gain Therapeutics presented initial data from its Phase 1b clinical study of GT-02287 in Parkinson's patients at an international congress. Early results showed improvements in MDS-UPDRS scores among participants, with the drug well-tolerated and no serious adverse events reported. The study has been extended to allow treatment for up to 12 months.
Read more →GANXGain Therapeutics to Participate at Drug Discovery Innovation Programme 2025
Gain Therapeutics, Inc. will participate in the Drug Discovery Innovation Programme 2025, where Dr. Rinaldo Montalvão will present on AI in drug discovery. The event will take place in Barcelona, Spain, on September 25-26. Gain is known for its allosteric therapies and is currently evaluating its lead candidate, GT-02287, for Parkinson's disease.
Read more →GANX▲ +7.6%on this newsshared move
Gain Therapeutics Begins Its GT-02287 Phase 1b Extension Study in People with Parkinson’s Disease
Gain Therapeutics has initiated a Phase 1b extension study for GT-02287, allowing participants to continue treatment for an additional nine months after the initial 90-day dosing. The study, which enrolled 21 subjects, is expected to conclude in December 2025. Early results will be presented at the upcoming International Congress of Parkinson’s Disease and Movement Disorders in October 2025, showcasing data on safety, tolerability, and functional impacts.
Read more →GANXThe Parkinson’s Caregiver: 7 Ways To Help Your Loved One
The article offers seven essential tips for caregivers of individuals with Parkinson's Disease, emphasizing the importance of creating a supportive home environment, encouraging physical activity, and ensuring timely medication. It highlights the need for open communication and proper nutrition while also addressing the emotional and mental health challenges faced by patients. Caregivers are encouraged to stay informed about the disease and available resources.
Read more →GANX▼ -9.4%on this news
Gain Therapeutics Receives Australian Approval of Phase 1b Dosing Extension and Reports Positive Independent Data Monitoring Committee Recommendation
Gain Therapeutics has received approval to extend the dosing period of its Phase 1b trial for GT-02287 by an additional nine months. The independent data monitoring committee has recommended continuing the study without changes, indicating no safety concerns. This extension allows participants to receive treatment for a total of 12 months, reflecting positive feedback from both patients and clinicians.
Read more →GANXGain Therapeutics Reports Financial Results for Second Quarter 2025 and Provides Corporate Update Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson's Disease (PD) with or without GBA1 mutations du
Gain Therapeutics has reported positive financial results for Q2 2025, including the early completion of patient enrollment for its Phase 1b study of GT-02287 in Parkinson's disease. The company anticipates having analysis results available in Q4 2025, which will assist in planning for their Phase 2 trial. In addition, Gain has experienced a decrease in research and development expenses due to various income sources, although net loss, cash reserves, and certain costs remain areas of concern.
Read more →GANXGain Therapeutics to Present at BTIG Annual Virtual Biotechnology Conference
Gain Therapeutics, Inc. will present at the BTIG Annual Virtual Biotechnology Conference on July 30, 2025. The company's management will engage in a fireside chat and one-on-one meetings. Gain is focused on developing allosteric therapies, with its lead candidate, GT-02287, currently in a Phase 1b trial for Parkinson's disease.
Read more →GANXGain Therapeutics Announces Pricing of $7.0 Million Public Offering
Gain Therapeutics, Inc. has announced a pricing of $7.0 million for a public offering, involving 4,501,640 shares of its common stock along with associated warrants. The price for each set of two shares and one warrant is set at $3.11. This capital is intended to aid in the ongoing clinical and nonclinical development of their lead candidate, GT-02287, which targets neurodegenerative diseases. The offering is expected to close on or about July 17, 2025, depending on customary closing conditions.
Read more →GANX▼ -8.6%on this newsshared move
Gain Therapeutics Announces Proposed Public Offering BETHESDA, Md.
Gain Therapeutics, Inc. has announced a proposed public offering of its common stock and warrants to finance the development of its lead drug candidate, GT-02287, aimed at treating neurodegenerative diseases. The final terms of the offering, including the number of shares and warrants, will depend on market conditions. Gain's lead candidate is currently undergoing a Phase 1b clinical trial for Parkinson's disease, and the company plans to use the net proceeds for clinical development and corporate purposes. The offering will be managed by Newbridge Securities Corporation and involves risks typical of biotech funding endeavors.
Read more →GANX▼ -8.6%on this news· ran to -20% by day 1
Gain Therapeutics Announces Completion of Target Enrollment in Phase 1b Clinical Study Evaluating GT-02287 in People With Parkinson’s Disease With or Without a GBA1 Mutation
Gain Therapeutics announced the completion of target enrollment in its Phase 1b clinical study evaluating GT-02287 for Parkinson's disease, achieving 16 participants ahead of the goal. The 90-day biomarker analysis from cerebrospinal fluid will be available in Q4 2025 instead of Q1 2026, demonstrating accelerated timelines for potential results. The study will continue patient screening through July 31, 2025, as there is notable interest from clinicians and patients. No serious adverse events have been reported during the study, which focuses on assessing the safety and tolerability of GT-02287.
Read more →GANXIs your loved one ready for a clinical trial?
The article discusses the personal decision-making process for caregivers considering clinical trials for their loved ones. It outlines the phases of clinical trials, the importance of informed consent, and the role of communication between caregivers, patients, and healthcare teams. It emphasizes that clinical trials can be beneficial at various stages of treatment, not just as a last resort.
Read more →GANXAdvancing GBA1 Research: A Glimpse into GBA1 Canada’s Mission and Impact
GBA1 Canada (G-Can) is an initiative focused on advancing research related to the GBA1 gene, which is significant in Parkinson's disease and Lewy body dementia. The organization aims to develop targeted therapies and initiate clinical trials within five years. G-Can collaborates with various esteemed partners and engages the community through events like the GBA1 Meeting.
Read more →GANXGain Therapeutics to Participate in Upcoming Investor Conferences
Gain Therapeutics, Inc. has announced the participation of its CEO, Gene Mack, in two investor conferences. These conferences will include a fireside chat at the H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference and a corporate presentation at BIO 2025. The company's lead drug candidate, GT-02287, is being evaluated for Parkinson's disease in a Phase 1b trial, and Gain Therapeutics is focusing on developing allosteric therapies with a diverse pipeline targeting multiple diseases.
Read more →GANXGain Therapeutics Announces Oral Presentation at 2nd GBA1 Meeting
Gain Therapeutics, Inc. announced they will have an oral presentation at the GBA1 Meeting 2025, scheduled for June 5th-7th in Montreal, Canada. Jonas Hannestad, M.D., Ph.D., the Chief Medical Officer, will present details about the company's lead drug candidate, GT-02287, currently being evaluated in a Phase 1b clinical trial for Parkinson's disease and other conditions. The company is a clinical-stage biotechnology firm focused on the advancement of next-generation allosteric therapies.
Read more →GANXWhat Trial Enrollment Looks Like: From Preclinical Screenings to Participation
The article outlines the clinical trial enrollment process, detailing steps from preclinical screenings to participant involvement. It explains the importance of informed consent and the various phases of clinical trials, emphasizing their role in advancing medical treatments. The piece highlights the rigorous criteria for participant eligibility and the monitoring involved throughout the trial.
Read more →GANX▲ +11%on this news
What Is Mitochondrial Complex I and Its Role in Health?
Mitochondrial complex I plays a crucial role in the electron transport chain, facilitating ATP production. Deficiencies in this complex can lead to significant health issues, including Parkinson's disease, primarily linked to GCase dysfunction. Gain Therapeutics has completed a phase 1 trial for GT-02287, a small molecule aimed at enhancing GCase function and mitochondrial health.
Read more →GANXGain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update First Biomarker Analysis from Phase 1b Study of GT-02287 in Parkinson ' s Disease Expected Mid-2025 BETHESDA, Md.
Gain Therapeutics has reported its financial results for Q1 2025, highlighting the successful initiation of the Phase 1b study of GT-02287 for Parkinson's disease. The company anticipates completing enrollment by July 2025 and expects the first biomarker analysis results in mid-2025. There was a slight decrease in R&D expenses, while G&A expenses increased due to legal and professional fees. Gain maintains a strong cash position of $9.1 million as it advances its clinical programs.
Read more →GANXWalking Together for a Cure: The 2025 Parkinson’s Unity Walk
The 2025 Parkinson's Unity Walk, held on April 26 in Central Park, raised over $2.2 million for Parkinson's disease research, marking a record for the event. Hosted by The Michael J. Fox Foundation, the walk celebrated 31 years of collective efforts to increase awareness and funding for Parkinson's disease. Donations continue to be accepted to support ongoing initiatives.
Read more →GANX12 Self-Care Tips for Parkinson’s Disease
The article presents 12 self-care tips for individuals diagnosed with Parkinson's disease, emphasizing the importance of physical activity, a balanced diet, and emotional health. It highlights the role of hobbies, assistive devices, and maintaining a routine in enhancing the quality of life. Additionally, it addresses the needs of caregivers, advocating for their self-care and support.
Read more →GANXGT-02287 Parkinson’s Drug Research Update — Preclinical Data & Phase 1b Design
Gain Therapeutics presented updates on GT-02287 at the AD/PD 2025 Conference, highlighting new preclinical data and the design of its Phase 1b study. GT-02287 is an allosteric enzyme modulator aimed at treating Parkinson's disease, showing promising results in preclinical models. The ongoing Phase 1b study will assess safety and pharmacokinetics in participants with Parkinson's disease.
Read more →GANXSupporting Parkinson’s Awareness During April: How You Can Make a Difference
April is designated as Parkinson's Awareness Month, aimed at raising awareness and supporting individuals affected by Parkinson's disease. The article outlines various fundraising events scheduled for April 2025, encouraging community participation and donations to support research and resources for those living with Parkinson's. It also emphasizes the importance of education and reducing stigma associated with the disease.
Read more →GANXGain Therapeutics Presents Additional Preclinical Data and Design of Phase 1b Clinical Study of GT-02287 at AD/PD 2025 and Provides Enrollment Update GT-02287 oral presentation demonstrates new evidence of disease-modify
Gain Therapeutics has shared new preclinical data and the design of its Phase 1b clinical study for GT-02287 at the AD/PD 2025 conference. The data indicates promising disease-modifying activity for GT-02287 in preclinical models of both GBA1 and idiopathic Parkinson's disease. An initial biomarker analysis is set for mid-2025, while complete analysis of the Phase 1b endpoints will be available by late 2025. The company is optimistic about the ongoing enrollment and the therapeutic potential of GT-02287 in treating Parkinson's disease.
Read more →GANXThe Upcoming AD/PD 2025 Conference
The AD/PD Conference 2025 will be held from April 1-5 in Vienna, Austria, focusing on advancements in Alzheimer's and Parkinson's diseases. This annual event will showcase new research, including biomarker discoveries and gene therapy. It aims to foster collaboration among global experts to enhance understanding and treatment of these conditions.
Read more →GANXGain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update First Analysis from Phase 1b Study of GT-02287 in Parkinson ' s Disease Expected in Q2 2025 BETHESDA, Md.
Gain Therapeutics reported its financial results for Q4 2024 and provided a corporate update regarding its lead drug candidate GT-02287 for Parkinson's disease. The company experienced a decrease in both research and development and general administrative expenses compared to the previous year, reflecting improved financial efficiency. A first analysis from the Phase 1b trial of GT-02287 is anticipated in Q2 2025, which could serve as a significant value inflection point for the company as it plans for further development phases. Despite these advancements, Gain still reported a considerable net loss for the year.
Read more →GANXUnified Parkinson’s Disease Rating Scale (UPDRS) Explained
The Unified Parkinson’s Disease Rating Scale (UPDRS) is a key tool for assessing Parkinson's disease severity, covering motor and non-motor functions. It includes four parts, with the recent MDS-UPDRS update enhancing its effectiveness. The scale is widely used in clinical practice and research to monitor symptom progression and evaluate treatment efficacy.
Read more →GANX▲ +8.2%on this news
Gain Therapeutics CEO Gene Mack Issues Letter To Shareholders and Provides Operational Update BETHESDA, Md.
Gain Therapeutics, Inc. provided a shareholder update highlighting key milestones for 2025, particularly the advancement of its clinical trial for GT-02287, aimed at treating Parkinson's disease. The company received approval to initiate Phase 1b trials and demonstrated safety and efficacy in earlier studies. With ongoing support from the FDA, they aim to complete interim analyses and further investigate biomarkers associated with the disease. The management expresses optimism about the potential impact of GT-02287 and the company's financial stability through 2025.
Read more →GANX▼ -7%on this news
Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, F
Gain Therapeutics announced the promotion of Gene Mack to Chief Executive Officer and Board Member, effective January 6, 2025. Mack has served as CFO since April 2024 and interim CEO since June 2024. His leadership is expected to maintain alignment between the company's short-term and long-term objectives as it progresses with its drug candidate, GT-02287, in clinical trials for Parkinson's disease. Gianluca Fuggetta will assume the role of Senior Vice President, Finance.
Read more →GANXGain Therapeutics Initiates Phase 1b Clinical Trial of Lead Candidate GT-02287 in People with GBA1 and Idiopathic Parkinson's Disease The Company has received approval to begin enrollment of the Phase 1b clinical trial i
Gain Therapeutics has announced the initiation of a Phase 1b clinical trial for its lead candidate, GT-02287, intended for individuals with GBA1 and idiopathic Parkinson's Disease. The trial, approved in Australia, aims to evaluate the drug's safety, tolerability, and its impact on biomarkers over three months. GT-02287 was previously found to be safe and well-tolerated and showed significant engagement with the GCase target in earlier studies. Enrollment for the trial is expected to conclude in spring 2025, with results anticipated by mid-2025.
Read more →GANX▼ -14%on this news
Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update Initiation of Phase 1b Study of GT-02287 in Parkinson ' s patients expected by end of 2024 BETHESDA, Md.
Gain Therapeutics, Inc. has announced its financial results for Q3 2024 and provided an update on its corporate activities. Significant progress was made with its lead candidate, GT-02287, aimed at treating Parkinson's disease, demonstrated by favorable results from a Phase 1 study. The company is on track to initiate a Phase 1b study by the end of 2024 and plans to meet with the FDA before year-end to facilitate further development. Additionally, Q3 financial results indicated increased research expenses, though net losses per share decreased compared to the previous year.
Read more →GANXParkinson’s Disease Therapeutics by Michael J. Fox Foundation 2024
The Michael J. Fox Foundation will host its 16th Annual Parkinson’s Disease Therapeutics Conference on October 17, 2024, in New York City. The event will focus on advancements in therapeutic strategies, including novel treatments and biomarkers for early detection. Notable speakers and poster presentations will contribute to discussions on patient engagement and innovative research.
Read more →GANX▲ +17.3%on this news
Gain Therapeutics Presents Preclinical GT-02287 Data at Neuroscience 2024 GT-02287 Demonstrates Disease Modifying Capacity in Both GBA1 and Idiopathic Parkinson's Disease Models GT-02287 Improves Mitochondrial Function a
Gain Therapeutics, Inc. presented promising preclinical data on GT-02287 at the Neuroscience 2024 conference, highlighting its disease-modifying capacity in models of both GBA1 and idiopathic Parkinson's disease. The findings indicate that the treatment not only restores motor and cognitive functions but also improves mitochondrial health and prevents Tau accumulation. These results suggest that GT-02287 may have broader therapeutic implications, including potential use in treating Alzheimer's disease. The study underscores the significant progress made by Gain Therapeutics in developing GT-02287 for these neurological conditions.
Read more →GANXHuman Clinical Trials: Single & Multiple Ascending Dose (SAD & MAD) Studies
Gain Therapeutics has completed the SAD and MAD studies for GT-02287, a drug candidate for Parkinson's disease. The Phase 1 study involved 72 healthy volunteers and reported no serious adverse events. GT-02287 demonstrated safety and tolerability, with significant therapeutic effects observed in preclinical models, including improved motor function and reduced neuroinflammation.
Read more →GANXH.C. Wainwright Global Investment Conference & International Congress of Parkinson’s Disease and Movement Disorders
Gain Therapeutics is set to participate in two significant conferences in September 2024. The H.C. Wainwright Global Investment Conference will feature insights from industry leaders, while the International Congress of Parkinson’s Disease and Movement Disorders will highlight advancements in treatment and research. Gain Therapeutics will present a novel glucocerebrosidase chaperone, GT-02287, during these events.
Read more →GANXRyan Reynolds Shares His Father’s Early Parkinson’s Symptoms: Subtle Signs His Family Missed
Ryan Reynolds discusses his father's struggle with Parkinson's disease, highlighting early symptoms that were missed by his family. The article emphasizes the importance of recognizing both motor and non-motor symptoms for early detection. Reynolds advocates for awareness and education to help others identify these signs sooner, improving management of the disease.
Read more →GANXBiomarkers and Their Role in Neurodegenerative Diseases
The article discusses the importance of biomarkers in diagnosing and treating neurodegenerative diseases. It highlights the limited number of approved biomarkers, particularly for Alzheimer's disease, and emphasizes the role of new biomarkers like Neurofilament light chain (NfL) in identifying various neurological disorders. The potential of these biomarkers to improve patient outcomes is underscored.
Read more →GANXGain Therapeutics Discusses with Ram Selvaraju at H.C. Wainwright’s Annual Neuro Perspectives Virtual Conference
At the H.C. Wainwright Annual Neuro Perspectives Virtual Conference, Gain Therapeutics discussed its innovative drug discovery platform and lead candidate GT-02287, aimed at treating Parkinson's disease. CFO Gene Mack emphasized the unique design of small molecules for targeted drug interactions and shared insights on the company's focus on the GBA1 subset of Parkinson's. The discussion also highlighted promising preclinical results and the company's plans for future clinical trials.
Read more →GANXGT-02287: A Promising GCase Enhancer for GBA1 Parkinson’s
Gain Therapeutics is advancing its lead drug candidate, GT-02287, for treating GBA1 Parkinson's disease. Currently in Phase 1 clinical development, GT-02287 has demonstrated significant improvements in cognitive function and daily activities in preclinical models. The therapy enhances glucocerebrosidase function, addressing the underlying causes of the disease. The findings suggest a promising future for this innovative treatment.
Read more →GANXThe role of the immune system in neurodegenerative diseases
The article discusses the significant role of the immune system in neurodegenerative diseases, including Alzheimer's and Parkinson's. Chronic inflammation is highlighted as a key factor, potentially leading to tissue damage and disease progression. Future therapies may target immune responses to improve treatment outcomes and slow disease advancement. Ongoing research aims to clarify the relationship between inflammation and neurodegeneration.
Read more →GANXDiscovery of allosteric regulators with clinical potential to stabilize alpha-L-iduronidase in mucopolysaccharidosis type I
The article discusses the discovery of GT-01803, an allosteric regulator for alpha-L-iduronidase, aimed at treating Mucopolysaccharidosis type I (MPS I). Using the SEE-Tx1 platform, researchers identified this compound, which improves enzyme stability and activity. The findings suggest potential for enhanced efficacy in existing enzyme replacement therapies and highlight the need for further clinical validation.
Read more →GANXA Finance Guy with a Fervor for Medicine
Gene Mack has been appointed as the new CFO of Gain Therapeutics, bringing over a decade of experience in the Life Sciences sector. His background in biochemistry and finance positions him uniquely to bridge the gap between science and business. Mack is optimistic about the company's future, particularly its lead program targeting Parkinson's disease, and aims to enhance clinical trial strategies and financial decision-making.
Read more →GANXThe connection between neurodegenerative diseases and template misfolding proteins
The article discusses the connection between neurodegenerative diseases like Alzheimer's and Parkinson's, focusing on template misfolding proteins. These misfolded proteins create aggregates that are neurotoxic and contribute to disease progression. Gain's therapeutic candidate, GT-02287, is in a Phase 1 trial and aims to inhibit the onset of these diseases, offering hope for future treatments.
Read more →GANXThe Path to Cure: The Power of Collaboration in Drug Development
In an interview with Dr. Jonas Hannestad, the Chief Medical Officer at Gain, he discusses the evolving collaboration between academia, industry, and the NIH in drug development. He highlights the importance of partnerships and the role of patient involvement in shaping clinical trials. Challenges such as intellectual property concerns and the complexities of genetic information are also addressed, emphasizing the need for continued dialogue and innovation in the field.
Read more →GANXDr. Jonas Hannestad Discusses Parkinson’s Disease & Drug Development
In an interview, Dr. Jonas Hannestad discusses advancements in drug development for Parkinson's disease, emphasizing the collaboration between academia and industry. He highlights the role of neuroimaging, particularly PET imaging, in diagnosing and understanding the disease. Dr. Hannestad also addresses the genetic link of GBA1 mutations to Parkinson's and the potential of new therapies targeting these mutations.
Read more →GANXCongress Passes Historic National Plan to End Parkinson’s Act
On May 23, 2024, Congress passed the National Plan to End Parkinson’s Act, a significant step towards addressing Parkinson's disease. The act, which received bipartisan support, mandates the creation of an advisory council to coordinate federal efforts in research, treatment, and prevention of the disease. This historic legislation aims to alleviate the financial burden of Parkinson's on patients and the healthcare system.
Read more →GANXGain Therapeutics Reports Financial Results for Second Quarter 2024 and Provides Corporate Update Topline Results From MAD Phase 1 Study of GT-02287 on Track for August 2024 With Full Presentation at Upcoming Medical Con
Gain Therapeutics, Inc. reported financial results for the second quarter of 2024, highlighting progress with their lead candidate GT-02287 targeting Parkinson's disease. The company announced that it is on track to release topline results from the MAD Phase 1 study in August 2024. Additionally, an initiation of a Phase 1b study is expected in Q4 2024, aimed at evaluating GT-02287's efficacy in Parkinson's patients. Although financial losses persist, the company is optimistic about meeting clinical milestones and advancing its drug development efforts.
Read more →GANX▲ +5.4%on this news· ran to +23% by day 3
Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (MAD) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson's Disease GT-02287 Well Tolerated With No Serious A
Gain Therapeutics has announced the successful completion of the dosing phase in the multiple ascending dose (MAD) part of its Phase 1 study for GT-02287, a novel therapy aimed at treating Parkinson's disease. The study involved 72 healthy subjects and reported no serious adverse events or premature discontinuations. Preliminary data reveals that GT-02287 was well tolerated with favorable safety profiles. The company plans to present further topline data in August 2024, with an intent to initiate clinical trials in Parkinson's patients by Q4 2024.
Read more →GANXGain Therapeutics, Inc. Appoints Gene Mack as Interim CEO Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md.
Gain Therapeutics, Inc. has appointed Gene Mack as Interim CEO following the departure of Matthias Alder. Mack, who serves as CFO, will retain his financial duties while Khalid Islam, the company's founder, steps in as Executive Chairman. The company is advancing its lead drug candidate, GT-02287, for Parkinson's disease, which has shown promising results in preclinical models. The appointment comes as the firm looks to sustain momentum in its clinical development efforts.
Read more →GANXGain Therapeutics Reports Financial Results for First Quarter 2024 and Provides Corporate Update BETHESDA, Md.
Gain Therapeutics, Inc. reported its financial results for Q1 2024, highlighting a decrease in both research and development expenses and general administrative expenses compared to the previous year. The company's lead program, GT-02287 for GBA1 Parkinson's disease, remains a focal point with anticipated clinical milestones ahead. Cash reserves totaled $12.7 million, decreased from $16.8 million at the end of 2023. Overall, the financial performance shows improved cost management and sustained optimism from the management team regarding clinical trials.
Read more →GANXGain Therapeutics Reports Positive Results from Phase 1 Trial of GT-02287 for GBA1 Parkinson’s
Gain Therapeutics has reported positive results from the Phase 1 trial of GT-02287, a novel therapy for GBA1 Parkinson's disease. The trial demonstrated safety and tolerability in healthy adults, with no serious adverse events. GT-02287 effectively restores GCase activity and reduces neuroinflammation. The company plans to advance to the multiple ascending dose phase in Q2.
Read more →GANX▲ +6.9%on this news
Interview: Jonas Hannestad, MD, on Medicine That Matters
Jonas Hannestad, the new Chief Medical Officer at Gain Therapeutics, discusses the importance of patient experience in drug development, particularly for neurodegenerative diseases. He emphasizes the need for empathy in medicine and the significance of understanding both the biological mechanisms and the quality of life for patients. As Gain prepares for patient studies, Hannestad expresses optimism about their innovative approach targeting GBA mutations associated with Parkinson's disease.
Read more →GANXWhen Is Parkinson’s Awareness Month and World Parkinson’s Day?
April is recognized as Parkinson's Awareness Month, with World Parkinson's Day celebrated on April 11th. Gain Therapeutics is developing GT-02287, a drug candidate aimed at treating GBA-Parkinson's disease, which affects over 500,000 patients globally. The Phase 1 clinical trial is set to complete in the first half of 2024, with a patient cohort planned for later in the year.
Read more →GANXGain Therapeutics’ Eric Richman on CNS Drug Discovery & Parkinson’s
Gain Therapeutics, represented by Eric Richman, discussed their innovative approach to treating neurodegenerative diseases, particularly Parkinson's, during a recent event. Utilizing their AI-driven Magellan platform, the company aims to develop small molecules that can correct protein misfolding. Their lead asset has shown promise in reversing Parkinson's symptoms in animal models, and they are currently conducting Phase 1 clinical trials. The focus on genetically defined patient populations may enhance treatment efficacy.
Read more →GANXGBA and Parkinson’s: Unlocking Precision Medicine Potential
The KOL event highlighted the potential of GBA mutations as a target for Parkinson's disease therapies. Professor Roy Alcalay discussed the genetic basis of GBA-associated Parkinson's, emphasizing its prevalence and the feasibility of clinical trials. Insights from Gaucher disease inform therapeutic strategies, while advancements in precision medicine pave the way for tailored treatments aimed at improving patient outcomes.
Read more →GANXDeciphering Parkinson’s Complexity: Insights from Professor Tiago Fleming Outeiro
Professor Tiago Fleming Outeiro discussed the complexities of Parkinson's disease at a KOL event, emphasizing the need for better classification and understanding of the disease. He highlighted advancements in biomarkers and neuroimaging that could improve diagnosis and treatment. Outeiro also pointed out the challenges faced in translating laboratory discoveries into effective therapies.
Read more →GANXAdvancing GT-02287: A Promising Treatment for Parkinson’s Disease
Gain Therapeutics is advancing GT-02287, a GBA modulator aimed at treating Parkinson's disease. The compound has shown efficacy in preclinical studies, addressing critical pathological features associated with the disease. It is currently undergoing Phase 1 clinical trials, with expectations for further development and potential as a disease-modifying therapy.
Read more →GANXGain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer BETHESDA, Md.
Gain Therapeutics has appointed Gene Mack as its new Chief Financial Officer, effective April 8, 2024. With over 25 years of experience in the life sciences sector, Mack is expected to enhance the company’s executive management team as it progresses its lead drug candidate, GT-02287, a potential treatment for GBA1 Parkinson's disease. The appointment is aligned with Gain's growth strategy and efforts to engage more with the investor community. Additionally, the company recently received funding support for its clinical programs, further establishing its position in the biotechnology field.
Read more →GANXGain Therapeutics Reports Financial Results for Year End 2023 and Provides Corporate Update BETHESDA, Md.
Gain Therapeutics, Inc. has reported its financial results for the year ended December 31, 2023, highlighting a net loss of $22.3 million, with increased expenses in both research and development and general administration. The company is optimistic about its lead program GT-02287 for GBA1 Parkinson's disease, showing promising results in Phase 1 trials. Gain Therapeutics anticipates that its current cash reserves will sustain operations until at least Q1 2025, supporting its operational plans amid continuous clinical advancements.
Read more →GANXRevolutionizing Treatment: Gain Therapeutics Leads the Way in AI-Driven Drug Discovery for Complex Diseases
Gain Therapeutics is advancing AI-driven drug discovery with its Magellan™ platform, targeting previously unreachable therapeutic targets. The drug GT-02287 shows potential as a leading treatment for Parkinson's Disease by addressing GCase misfolding. Additionally, the company is exploring treatments for A1AT deficiency, highlighting its commitment to innovative solutions in complex diseases. Despite challenges in AI drug development, the future remains promising.
Read more →GANXKOL/Analyst Event
Gain Therapeutics will host an R&D update event focusing on Parkinson's Disease on February 22, 2024. The event aims to engage KOLs, analysts, patient advocates, and investors. Key topics include GBA-associated Parkinson's Disease and the latest data on GT-02287, a promising treatment. Notable speakers include Matthias Alder and key opinion leaders from prestigious institutions.
Read more →GANXVarney & Co. 02/7/24
Gain Therapeutics was featured on Fox Business News for its innovative AI application in developing therapies for Parkinson's disease. The company's lead program shows promising preclinical data, indicating potential disease reversal in mice. Currently in clinical trials, this program aims to provide new treatment options beyond just symptom management.
Read more →GANX▼ -5.6%on this news
Presentation: GT-02287, a clinical stage GCase enhancer, displays neuroprotection and restores motor function in preclinical models of Parkinson’s disease following delayed administration
Beatriz Calvo-Flores Guzman presented promising preclinical data on GT-02287, a GCase enhancer, at the 20th Annual WORLDSymposium. The data showed that delayed administration of GT-02287 provided neuroprotection and restored motor function in models of Parkinson's disease. This small molecule may serve as a disease-modifying therapy for Parkinson's and other neurodegenerative conditions linked to GCase dysfunction.
Read more →GANXGAIN THERAPEUTICS'
Gain Therapeutics, Inc. (Nasdaq: GANX) has provided an operational update and letter to shareholders outlining its achievements and future plans. The company is advancing its lead drug candidate, GT-02287, for Parkinson's disease into clinical trials, with results expected by mid-2024. They have successfully raised financing and grant funds to support operations into 2025 and are optimistic about strategic partnerships to advance their R&D assets. Further data presentations are scheduled, showcasing their pipeline's potential.
Read more →GANX▼ -11.9%on this news
New Parkinson’s Treatment Progresses in Phase 1 Clinical Trial
Gain Therapeutics is advancing its lead program, GT-02287, aimed at treating GBA1-related Parkinson's disease. The company utilizes a unique computational platform to identify drug targets, which shows promise in clinical applications. The recent webinar highlighted the potential of their approach and the favorable M&A environment for biotech firms. Overall, Gain Therapeutics is positioned well for future growth.
Read more →GANX▲ +11%on this news
Beyond Numbers: Unpacking the Rich History of the J.P. Morgan Healthcare Conference
Gain Therapeutics will attend the J.P. Morgan Healthcare Conference from January 8-11, 2024, in San Francisco. The event has evolved from a small gathering in 1983 to a major healthcare event attracting global investors. It serves as a platform for networking, deal-making, and discussing future healthcare trends.
Read more →GANXGain Therapeutics Announces Third Quarter 2023 Financial Results and Business Update Phase 1 clinical study of GT-02287 initiated; dosing escalation on schedule BETHESDA, Md.
Gain Therapeutics, Inc. announced its financial results for the third quarter of 2023, highlighting the initiation of the Phase 1 clinical trial for GT-02287, aimed at treating GBA1 Parkinson's disease. The dosing escalation for the trial is progressing as planned. The company reported a net loss of $4.7 million during this quarter, slightly higher than the previous year, alongside an increase in research and development expenses. Despite the financial challenges, recent preclinical data showcases the drug's potential benefits in treating related neurodegenerative disorders.
Read more →GANXNature Scientific Reports links glucocerebrosidase (GCase) dysfunction and neurodegenerative diseases
Recent research published in Nature Scientific Reports reveals mechanisms connecting glucocerebrosidase (GCase) dysfunction and neurodegenerative diseases. The findings suggest that targeting GCase may provide therapeutic opportunities for conditions like Parkinson's and Alzheimer's. Gain Therapeutics' candidate GT-02287 shows potential in enhancing GCase functionality, which could alleviate lysosomal stress and tau accumulation.
Read more →GANXAlpha Synuclein: Implications Beyond Parkinson’s Disease
Gain Therapeutics has initiated a Phase 1 clinical trial for GT-02287, aimed at treating neurodegenerative diseases by stabilizing the GCase enzyme. This small molecule has demonstrated potential in depleting toxic substrates like alpha-synuclein, which is linked to Parkinson's disease and other synucleinopathies. GT-02287's unique mechanism targets the beginning of the disease cascade, suggesting broader therapeutic applications.
Read more →GANXGain Therapeutics: Developing New Medicines for Protein Misfolding Diseases
Gain Therapeutics is preparing to initiate clinical trials for its drug candidate GT-02287, aimed at treating Parkinson's disease. The company utilizes allosteric modulation to target misfolded proteins, specifically GCase, which is linked to the disease. Recent findings indicate that GT-02287 can restore GCase function and improve dopamine levels in animal models. The first phase one clinical study is expected to start later this year.
Read more →GANXThe Critical Importance of Neurodegenerative Disease Biomarkers
The article discusses the significance of biomarkers in neurodegenerative diseases, highlighting neurofilament light chain (NfL) as a promising new biomarker. The FDA's recent accelerated approval of tofersen for ALS based on NfL levels marks a significant advancement. Additionally, NfL's potential as an exploratory endpoint in clinical trials for Hunter Syndrome offers hope for better treatment evaluations.
Read more →GANXNew Parkinson’s Biomarker NfL: What You Should Know
Neurofilament light chain (NfL) is a protein that indicates neuronal cell death. Elevated NfL levels in blood and brain fluid are linked to severe symptoms and cognitive decline in Parkinson's disease. NfL is being investigated as a biomarker for various neurodegenerative diseases and is being considered in drug approval processes.
Read more →GANX▼ -5.3%on this news
Gain Therapeutics Announces Second Quarter 2023 Financial Results and Business Update HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for
Gain Therapeutics reported its financial results for Q2 2023, highlighting the submission of an application for Phase 1 clinical trials of GT-02287. The CEO expressed optimism about the drug's positive preclinical results, which suggest potential benefits for various neurodegenerative diseases. However, the company also reported an increased net loss and rising research and administrative costs, raising concerns about its financial sustainability. Nevertheless, its cash position appears adequate to support operations through mid-2024.
Read more →GANXLetting the Data Lead the Way: An interview with Terenzio Ignoni, SVP Quality and CMC – PART 2
In an interview, Terenzio Ignoni, SVP of Quality and CMC at Gain, discusses the evolving relationship with regulatory agencies like the FDA and EMA, emphasizing collaboration and transparency. He reflects on past challenges, including a refusal to file with the FDA, and highlights the importance of data-driven decision-making in drug development. Ignoni also shares insights on the cultural differences in planning and execution across countries, particularly in the context of developing treatments for CNS conditions like Parkinson's Disease.
Read more →GANXLetting the Data Lead the Way: An interview with Terenzio Ignoni, SVP Quality and CMC – PART 1
Dr. Terenzio Ignoni, SVP of Quality and CMC at Gain Therapeutics, discusses the importance of a data-driven approach in drug development. He oversees the transition from preclinical to clinical phases, emphasizing the need for stringent quality standards and risk management. Ignoni's experience in the pharmaceutical industry informs his strategies to enhance the likelihood of successful drug approvals.
Read more →GANXDr. Terenzio Ignoni “Let the Data Lead the Way”
Dr. Terenzio Ignoni, SVP of Technical Operations at Gain Therapeutics, emphasizes the importance of data in drug development. With over 23 years of experience, he has successfully navigated the complexities of FDA and EMA interactions. His unique insights and tenacity drive the company's mission to deliver essential treatments to patients.
Read more →GANXGAIN THERAPEUTICS REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS AND BUSINESS UPDATE Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson's disease Company is on track to submit applica
Gain Therapeutics, Inc. reported its financial results for the first quarter of 2023, revealing a net loss of $5.1 million and increased research and development expenses due to advancements in its lead program GT-02287 for GBA1 Parkinson's disease. The company emphasized successful GLP toxicology studies for GT-02287 and secured non-dilutive funding to support its research programs. Gain's cash and marketable securities totaled approximately $18.8 million as of March 31, 2023, which, along with anticipated grant funding, is expected to sustain operations into the third quarter of 2024. The company is positioning itself for significant clinical advancements and expanding its team with a new Chief Financial Officer.
Read more →GANXGain Therapeutics Appoints C. Evan Ballantyne as Chief Financial Officer BETHESDA, MD
Gain Therapeutics, a biotechnology firm, has appointed C. Evan Ballantyne as its new Chief Financial Officer. This transition occurs as the company prepares to advance its lead clinical program for GBA1 Parkinson's disease. Ballantyne's extensive experience in financing and corporate strategy is anticipated to benefit the company as it evolves into a clinical-stage entity. His predecessor, Salvatore Calabrese, will assist in ensuring a smooth transition. Gain Therapeutics is expected to capitalize on its innovative drug discovery platform and further develop its pipeline in metabolic disorders and oncology.
Read more →GANXGAIN THERAPEUTICS REPORTS FULL YEAR 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Company expects completion of IND-enabling studies of GT-02287 in H1 2023 Submission of dossier to start Phase 1 clinical trial of GT-02287 i
Gain Therapeutics, Inc. reported its financial results for the full year ended December 31, 2022, indicating a net loss of $17.59 million, an increase from the previous year's loss. The company highlighted progress in its pipeline, particularly the upcoming submission for a Phase 1 clinical trial of GT-02287 aimed at GBA1 Parkinson's disease. Additionally, Gain secured grant funding for its research on Alpha-1 Antitrypsin Deficiency, showcasing the versatility of its research platform. Despite a solid pipeline, rising expenses and decreasing cash reserves raise concerns about its financial sustainability.
Read more →GANXGAIN THERAPEUTICS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Par
GAIN THERAPEUTICS, INC. REPORTS THIRD QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson's Disease Therapeutic, GT-02287 Promoted Matthias
Read more →GANXGAIN THERAPEUTICS Announces PROMOTION OF Matthias Alder TO chief executive officer Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a senior advisor to the Company BETHE
THERAPEUTICS Announces PROMOTION OF Matthias Alder TO chief executive officer Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a senior advisor to the Company BETHESDA, MD, September 20, 2022-- Gain Therapeutics, Inc. (Nasdaq
Read more →GANXGAIN THERAPEUTICS, INC. REPORTS second QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings, Further Validating Therap
GAIN THERAPEUTICS, INC. REPORTS second QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings, Further Validating Therapeutic Potential and Clinical Utility in Parkinson's Disea
Read more →GANXGAIN THERAPEUTICS, INC. REPORTS First QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potenti
GAIN THERAPEUTICS, INC. REPORTS First QUARTER 2022 FINANCIAL RESULTS AND BUSINESS UPDATE Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson's Disease and Gaucher's
Read more →GANXGain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update $36.88 Million in Cash as of
Gain Therapeutics, Inc. Reports Full Year 2021 Financial Results and Business Update $36.88 Million in Cash as of December 31, 2021, provides runway into second half of 2023 and a strong cash position to transition the Company's lead program into clinical trials Compelling pre
Read more →GANX▼ -5.4%on this news
Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BETHESDA, MD
Gain Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BETHESDA, MD, December 28, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric bindin
Read more →GANX▲ +10.3%on this news· ran to +24% by day 3
Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Pr
Gain Therapeutics, Inc. Reports Third Quarter 2021 Financial Results and Business Update Data from Patient-Derived iPSC Study Evaluating STAR Compounds Show Positive Effects on Disease Onset and Progression; Full Data Presented at MJFF's Parkinson's Disease Therapeutics Confere
Read more →GANXGain Therapeutics Appoints Matthias Alder as Chief Operating Officer BETHESDA, MD
Gain Therapeutics Appoints Matthias Alder as Chief Operating Officer BETHESDA, MD, October 19, 2021 - Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a biotechnology company focused on identifying and optimizing allosteric binding sites never before targeted i
Read more →GANXGain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology --- Granted Two Patents for Compound
Gain Therapeutics, Inc. Reports Second Quarter 2021 Financial Results and Business Update Announced Multi-Target Drug Discovery Collaboration with Zentalis Pharmaceuticals in Oncology Granted Two Patents for Compounds that Stabilize G-Case for Gauchers Disease and other Synucl
Read more →GANXGain Therapeutics, Inc. Reports First Quarter 2021 Financial Results Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strength
Gain Therapeutics, Inc. Reports First Quarter 2021 Financial Results Completed successful initial public offering and raised $46 million in gross proceeds Appointed four new independent board of directors to strengthen leadership team Signed a multi-target collaboration agree
Read more →GANXGain Therapeutics Inc. 4800 Hampden Ln, St 200 Bethesda, MD 20814 www.gaintherapeutics.com GAIN THERAPEUTICS PRESENTS POSITIVE IN VITRO & IN VIVO DATA ON ITS ORALLY BIOAVAILABLE BRAIN PENETRANT STAR COMPOUNDS FOR THE TRE
GAIN THERAPEUTICS PRESENTS POSITIVE IN VITRO & IN VIVO DATA ON ITS ORALLY BIOAVAILABLE BRAIN PENETRANT STAR COMPOUNDS FOR THE TREATMENT OF GBA1 PARKINSON'S DISEASE & RELATED -SYNUCLEOPATHIES AT THE XXVI IAPRD WORLD CONGRESS Compounds reverse the neurodegenerative process observe
Read more →Competitive Position
How GANX ranks across every disease it competes inCompetitive Position is a premium feature
See how GANX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial